News

Top news

Statements and background on the CRISPR patent landscape

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement
Dublin, Ireland and Seoul, Korea,
23 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and G+FLAS Life Sciences, Inc. (G+FLAS), a biotechnology company developing research tools and reagents associated with CRISPR technology, today announced a non-exclusive license agreement granting G+FLAS access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
ERS Genomics and ZeClinics sign CRISPR/Cas9 license agreement
DUBLIN, Ireland & Barcelona, Spain,
16 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and ZeClinics, a contract research organization using zebrafish to carry out services focused on analyzing the safety, efficacy and biomedical relevance of new compounds, today announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Vivlion GmbH signs worldwide license agreement with ERS Genomics for CRISPR/Cas9 patent portfolio
DUBLIN, Ireland & Frankfurt a.M., Germany, 1st December 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Vivlion GmbH, a startup company providing next generation CRISPR/Cas gRNA libraries and screening services for the global R&D market, today announced a non-exclusive license agreement granting Vivlion® access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services.

Questions and answers about CRISPR patents

CVC’s issued patents are to the composition and use of the core type 2 CRISPR/Cas9 complex to modify DNA in ANY ENVIRONMENT without limitation to uses in eukaryotic cells. CVC further has issued patents on single guide RNA (sgRNA) which greatly enhances the efficiency of CRISPR gene editing in many applications.

In the United States, Broad’s issued patents (currently subject to a PTAB initiated interference) are for certain methods of genome editing and uses only in eukaryotic cells. 

In December, 2012, Broad requested “accelerated examination” of its application. This meant the USPTO considered the application more quickly. CVC did not request accelerated examination when it applied for a patent in May, 2012.

CRISPR research is a large field that involves contributions from many talented scientists around the world. The USPTO had issued more than 570 patents as of September 2020, with claims to CRISPR and/or Cas9 to approximately 900 inventors from more than 200 applicant organizations. The European Patent Office (EPO) had issued more than 190 such patents to more than 460 inventors from about 110 applicant institutions. In addition, there have been more than 9,200 applications filed (and published but not yet granted) around the world.

Current CVC patent list can be viewed here.

Over the next several years, there will be many more patents issued in the CRISPR field, to many inventors from many institutions, in recognition of each individual’s contribution to advancing CRISPR technology.

Latest news

ERS Genomics and Setsuro Tech sign CRISPR/Cas9 license agreement

DUBLIN, Ireland & Tokushima, Japan, 10 March 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Setsuro Tech, a biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, today announced a non-exclusive license agreement granting Setsuro Tech access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan.

Read more